Sanofi and Lilly end lawsuit and discontinue similar disputes worldwide
Eli Lilly has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.
Pharmaceuticals, Biotechnology and Life Sciences
Eli Lilly has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.
Phase II study of its Cyramza (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival (PFS) for patients with locally advanced or metastatic urothelial carcinoma who failed prior platinum-based therapy.
Anavex Life Sciences Corp, a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS)…
Collagen Solutions plc, has announced that its subsidiary Collagen Solutions Inc. has signed a supply agreement with Turkish medical device company Yücel Medikal Ltd.
FDA has announced that the TF Supplements of Houston is voluntarily recalling the following product to the consumer level: RHINO…
Novartis has announced results of a Phase III pivotal study showing Afinitor (everolimus) tablets reduced the risk of progression by 52% vs placebo in patients with advanced, progressive, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin.
Allergan plc announced on Friday that it has launched a generic version of Janssen’s Invega (paliperidone extended-release tablets) in the…
Janssen-Cilag International NV has announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European…
Murphy Farm Hay and Feed Company of Louisburg North Carolina have initiated a voluntary limited recall of alfalfa hay due to…
The U.S. Food and Drug Administration has approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to…